Question Bank › Named counterparty roster suddenly upgraded in c

Named counterparty roster suddenly upgraded in caliber

Calls Tested
500
Answered YES
7
Hit Rate
1.4%
rare by design

Quanterix Corporation (QTRX) — this company's answers

NO on the Q3 2023 call 2023-11-07 B
The model's full reasoning — Q3 2023 call → NOWe need answer only YES or NO. Need evaluate transcript. Need determine if management describes caliber of counterparties recently stepped up, real business, early. Let's parse. Transcript: Quanterix Q3 2023. Management mentions partnerships: Johnson & Johnson Innovative Medicines signed new agreement and launched Lucent AD P-tau217 test. Eli Lilly presented analytical validation using Simoa platform. VUMC Medical Center in Amsterdam presented Phase 1 data, working with VUMC and ABBS on clinical trial. University of Pittsburgh study used CMO platform. Also mentions "new agreement with Johnson & Johnson Innovative Medicines" - that's a big pharma. Is that a caliber shift? Historically Quanterix had Lilly collaboration? They mention "our collaboration with Lilly continues and it's a very strong collaboration." So J&J is new. But is it described as recently begun transacting with visibly higher class than historical norm? They don't explicitly contrast. They say "we signed a new agreement with Johnson & Johnson Innovative Medicines and launched the Lucent AD P-tau217 blood based biomarker test, combining Quanterix ultra-sensitivity, Simoa Technology, and J&J P-tau217 antibodies." That is real business? It's an agreement and launch of test. But no details of payment/orders. Also "majority of economics to come from our LDT and kit sales" - not necessarily current revenue. Also "we want to get it into as many hands as possible." Is this a caliber shift? They already had Lilly, a major pharma. J&J is similar caliber. So not necessarily new higher class. Also "VUMC Medical Center in Amsterdam presented Phase 1 data" - that's a research collaboration, not necessarily business. "We are working with the VUMC and ABBS on a clinical trial" - not described as paying customer. "University of Pittsburgh" study used platform - research. No mention of "recently begun transacting with higher class" as a theme.

← Back to the full QTRX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the CALIBER OF COUNTERPARTIES NOW DOING REAL BUSINESS WITH THE COMPANY HAS RECENTLY STEPPED UP — that customers, partners, or institutions of a size, stature, or sophistication the company did not previously transact with are NOW actually buying, deploying, contracting, or committing — and does management present this upgraded roster as a recent change grounded in current transactions, with the associated business still early relative to what those relationships imply? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent development with all three present: (1) A CALIBER SHIFT, RECENTLY OCCURRED: management conveys — by naming counterparties, by describing their category unmistakably ('one of the largest X', 'a national system', 'a top-tier operator'), or by contrasting who buys now versus who used to — that the company has recently begun transacting with a visibly higher class of counterparty than its historical norm; (2) REAL CURRENT BUSINESS, NOT LOGOS: these upgraded counterparties are actually paying, ordering, deploying, or committing now, described with operating substance, not letters of intent, pilots without payment, or pipeline; and (3) EARLY RELATIVE TO THE RELATIONSHIP: management conveys that what these counterparties have taken so far is the beginning — initial orders, first phases, first deployments — with the fuller relationship still ahead of the reported results. Answer NO if the counterparties described are the same kinds the company has always served. NO if the higher-caliber parties are only prospects, in discussions, or unpaid evaluations. NO if the company is itself large so that big counterparties are unremarkable for it. NO if the relationships are mature and fully reflected in results. NO if the upgrade rests on one anecdote management treats as exceptional. NO if the caliber shift appears only in analyst flattery management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
NBTX Nanobiotix S.A. Q2 2023 2023-09-27 D
APPS Digital Turbine, Inc. Q1 2024 2023-08-08 D
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

ASAN · Q2 2022 → YESThe question is about whether management describes that the caliber of counterparties now doing real business with the company has recently stepped up. YES The transcript shows management describing a recent caliber shift to higher-tier enterprise counterparties (Fortune 50 companies with tens of thousands of seats, ViacomCBS, Fujitsu, etc.) that are now conducting real business through larger deals, multiyear agreements, and wall-to-wall deployments.
APPS · Q1 2024 → YESThe question is about whether management describes that the caliber of counterparties now doing real business with the company has recently stepped up. YES Management describes a clear caliber shift with SingleTap: first revenues generated with TikTok (a top-tier social platform), launching with LinkedIn (another major social media company), and expecting a revenue-generating pilot with another large social media company.
EVGO · Q2 2022 → YESThe question is about whether management describes that the caliber of counterparties has recently stepped up, with real current business that's still early.

More from the question bank

The economics improved before the volume arrGeographic or market replication just starteRegular buyers moved from occasional to progConstraint-side candorManagement describes competitors unable to rPhysical throughput records at the operatingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.